Dogan O, Sahinli H, Duzkopru Y, Akdag T, Kocanoglu A. Is sarcopenia effective on survival in patients with metastatic gastric cancer? World J Gastrointest Oncol 2024; 16(5): 1861-1868 [PMID: 38764843 DOI: 10.4251/wjgo.v16.i5.1861]
Corresponding Author of This Article
Ozlem Dogan, PsyD, Staff Physician, Department of Medical Oncology, Adıyaman University Training and Research Hospital, No. 13 1164 Sk, Adiyaman 02100, Turkey. drozlemdogan@hotmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Ozlem Dogan, Department of Medical Oncology, Adıyaman University Training and Research Hospital, Adiyaman 02100, Turkey
Hayriye Sahinli, Yakup Duzkopru, Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Turkey
Tuba Akdag, Department of Radiology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara 06000, Turkey
Abdulkadir Kocanoglu, Department of Medical Oncology, Ankara Ataturk Sanatoryum Training and Research Hospital, Ankara 06170, Turkey
Author contributions: Dogan O took part in the planning, data collection, ethics committee application, and writing of the manuscript; Sahinli H contributed to the statistical analysis and writing of the data; Duzkopru Y contributed to the planning and data collection of the manuscript; Akdag T evaluated and measured radiology images; Kocanoglu A contributed to data collection.
Institutional review board statement: The study was reviewed and approved by the Health Sciences University Diskapi Yildirim Beyazit Training and Research Hospital Ethics Committee (Approval No. 119/05).
Informed consent statement: The institutional review board waived the need for informed consent due to the study’s retrospective methodology.
Conflict-of-interest statement: The authors declare having no conflicts of interest.
Data sharing statement: Raw data were generated at Health Sciences University Diskapi Training and Research Hospital. Derived data supporting the findings of this study are available from the corresponding author upon request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ozlem Dogan, PsyD, Staff Physician, Department of Medical Oncology, Adıyaman University Training and Research Hospital, No. 13 1164 Sk, Adiyaman 02100, Turkey. drozlemdogan@hotmail.com
Received: December 19, 2023 Peer-review started: December 19, 2023 First decision: December 28, 2023 Revised: January 16, 2024 Accepted: March 5, 2024 Article in press: March 5, 2024 Published online: May 15, 2024 Processing time: 142 Days and 1.7 Hours
Abstract
BACKGROUND
Sarcopenia is a progressively diminishing state characterized by the reduction of muscle mass and density, which is frequently observed in malignancies of solid organs.
AIM
To assess how sarcopenia affects the overall survival of individuals who have been diagnosed with metastatic gastric cancer.
METHODS
The study retrospectively included individuals who had been diagnosed with metastatic gastric cancer between January 2008 and December 2020. Sarcopenia was identified through the calculation of the average Hounsfield units (HUAC) using computed tomography (CT) images taken at the time of diagnosis in patients.
RESULTS
A total of 118 patients with metastatic gastric cancer were evaluated. Sarcopenia was detected in 29 patients (24.6%). The median survival of all patients was 8 (1-43) mo. The median survival of patients with sarcopenia was 2 mo, while it was 10 mo for those without sarcopenia (P < 0.001). A significant relationship was found between sarcopenia and survival.
CONCLUSION
Sarcopenia has been observed to impact survival outcomes in various types of solid tumor cancers. Sarcopenic patients can be identified in a short time, easily and inexpensively, by HUAC measurements from CT images used for diagnosis, and survival could be promoted with nutritional support.
Core Tip: In our study, the median survival of patients with sarcopenia was 2 mo, while it was 10 mo for those without sarcopenia and it was a statistically significant difference. Sarcopenia has an impact on the survival rates of individuals with solid tumors. If we can quickly identify sarcopenic patients through the Hounsfield units’ measurement at the time of diagnosis, contribute to survival by furnishing these patients with the requisite nutritional assistance before treatment.